A significant efficacy of nivolumab compared to placebo was observed in patients with tumor PD-L1 (CPS ≥ 1%), low baseline blood NLR, and normal baseline serum Na in terms of PFS and OS, while no differences in efficacy were observed under the opposite conditions (tumor PD-L1 CPS < 1%, high NLR, and hypoNa at baseline serum). The gene discussed is CD274; the disease is neoplasm.